Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Aggregated Volume: 719.536 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase in the notional interest in Ordinary Shares for Mr. R G Connor, President of Global Manufacturing & Supply. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The scope is limited strictly to the disclosure of the PDMR transaction.
Key Facts for Investor Verification
- Verify the total shareholding of Mr. R G Connor following this transaction to assess insider ownership levels.
- Confirm the terms of the 2009 Deferred Annual Bonus Plan to understand the mechanics of the dividend re-investment and matching shares.
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or other earnings releases for financial metrics.